Intellect Neurosciences, Inc. (OTCBB: ILNS) announced that they have completed the grant requirements to obtain a European patent regarding the company’s ANTISENILIN® antibodies product. They have also received a notice of allowance which states that future products to be developed by the company are approved for the treatment of Alzheimer’s disease. The company’s stock rose 68.75% during Thursday’s trading, and an additional 7.41% April 11.
The company has patents for their product, ANTISENILIN® antibodies, in Japan, China, and other countries to be disclosed. Currently, patent applications are in the approval stages in the United States. Dr. Daniel Chain, the company’s Chairman and CEO, is the sole inventor of ANTISENILIN®.
Dr. Chain commented on the recent news, “The use of ANTISENILIN® monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer’s disease. In addition to the Company’s products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies.”
Alzheimer’s disease is combated by immunotherapy that involves producing an antibody molecule that will bind to the endogenous beta-amyloid toxin, resulting in a clear path to the brain. This can happen in two different ways; by provoking the patient’s immune system to generate such an antibody (active immunization), or by administering an externally generated antibody (passive immunization). Results have proven that both procedures hold the potential to slow or arrest disease progression, providing key safety issues are incorporated.
“Intellect’s ANTISENILIN® antibody technology incorporates an important safety feature (“free-end specificity”), meaning that antibodies developed using the technology are designed to specifically block the neurotoxicity of beta amyloid, which accumulates in the brains of Alzheimer’s patients. The blocking of the neurotoxicity is achieved by promoting clearance of beta amyloid away from sites of damage while minimizing the potential for adverse effects,” stated Professor Donald Price, Professor of Pathology at John Hopkins School of Medicine.
“Dr. Chain’s idea of using antibodies in this way to reduce amyloid toxicity in the brain has gained considerable momentum over the past few years and we are currently optimistic that drugs of this type herald an exciting new era of drug development for safe and efficacious disease-modifying treatments for this devastating disease,” he added.
Let us hear your thoughts below:
